<DOC>
	<DOC>NCT02625376</DOC>
	<brief_summary>This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.</brief_summary>
	<brief_title>Resveratrol for Exudative Age-Related Macular Degeneration</brief_title>
	<detailed_description>Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration. Comparison of incidence of choroidal neaovascularization between each study group will be performed.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Men or women aged 55 or more with unilateral exudative AMD Visual acuity less or equal to 20/25 in the most affected eye Allergy to an investigational product atrophic AgeRelated Macular Degeneration or age related maculopathy significant media opacities Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy) Recent Cataract surgery Previous history of vitrectomy Acute or chronic severe organ failure Present participation in other clinical research study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>